Oxaliplatin Accord Healthcare 5 mg/ml concentraat voor oplossing voor infusie
Sponsors
Hopital Erasme, Groupe Belge D'Oncologie Digestive, UZ Leuven
Conditions
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMAPancreatic adenocarcinomacolorectal cancer
Phase 2
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma:
a randomised comparative multicentre phase II study (STEREOPAC)
RecruitingCTIS2022-501181-22-01
Start: 2023-02-06Target: 256Updated: 2024-01-10
“NALPAC” A NON-COMPARATIVE RANDOMIZED PHASE 2 STUDY, EVALUATING THE EFFICACY OF 5-FU + NALIRI AND 5-FU + NALIRINOX FOR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), PROGRESSIVE AFTER GEMCITABINE-ABRAXANE OR GEMCITABINE MONOTHERAPY.
RecruitingCTIS2024-516336-97-00
Start: 2022-02-21Target: 134Updated: 2025-02-25
A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients
Not yet recruitingCTIS2025-523261-25-00
Target: 13Updated: 2026-02-27